METHOD FOR DETERMINING THE INHIBITORY POTENTIAL OF BLOOD FOR PREDICTING UNCONTROLLED ACTIVATION OF COMPLEMENT SYSTEM IN COVID-19 Russian patent published in 2024 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: invention relates to medical immunology. Disclosed is a method for determining the inhibitory potential of blood for predicting uncontrolled activation of the complement system in COVID-19 by conducting a lysis reaction of erythrocytes of sheep sensitized by rabbit antibodies (EA), human blood serum in conditions of Veronal salt buffer VBS²⁺ at temperature 37.0±0.5 °C, samples are incubated for 10 minutes, complement-dependent EA lysis reaction is evaluated turbidimetrically by reducing the optical density of the EA suspension at wavelength of 620 nm, a calibration curve of optical density A₆₂₀ versus EA lysis is plotted to determine the degree of erythrocyte lysis in the test samples. At the same time complement system activity in corresponding EDTA-plasmas is determined, consumption of complement during blood coagulation is calculated as difference of degree of lysis in EDTA-plasma and blood serum, difference of complement activity in serum and EDTA-plasma at the level ±10% characterizes the optimal level of inhibitory potential of blood, higher complement activity of more than 10% in serum compared to EDTA-plasma indicates low functional activity of C1-inhibitor, lower activity of 10% to 45% of complement in blood serum characterizes reduced inhibitory potential mainly due to antithrombin III and very low complement activity in blood serum compared to EDTA-plasma of more than 45% is assessed as a threat of uncontrolled activation of complement, a threat of acute respiratory distress syndrome in COVID-19.

EFFECT: invention provides an assessment of the inhibitory potential of blood for predicting uncontrolled activation of the complement system in COVID-19 in routine studies.

1 cl, 5 dwg, 1 tbl, 3 ex